Insulet Corp
GOV
Company Profile
Business description
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
Contact
100 Nagog Park
ActonMA01720
USAT: +1 978 600-7000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
5,400
Stocks News & Analysis
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
stocks
This US AI winner has been unstoppable. Is it time to sell?
Astonishing results have driven this AI stock into significantly overvalued territory.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,855.90 | 79.60 | -0.89% |
| CAC 40 | 8,199.29 | 18.95 | -0.23% |
| DAX 40 | 24,616.22 | 142.83 | -0.58% |
| Dow JONES (US) | 50,768.32 | 98.46 | -0.19% |
| FTSE 100 | 10,373.20 | 5.15 | 0.05% |
| HKSE | 24,657.06 | 304.89 | -1.22% |
| NASDAQ | 25,917.53 | 208.10 | 0.81% |
| Nikkei 225 | 64,024.60 | 2,563.52 | -3.85% |
| NZX 50 Index | 13,038.24 | 123.73 | -0.94% |
| S&P 500 | 7,403.70 | 19.96 | 0.27% |
| S&P/ASX 200 | 8,625.10 | 80.00 | -0.92% |
| SSE Composite Index | 3,959.34 | 68.40 | -1.70% |